



Definitive Announcement of the Final Result

of the public tender offer by

Pharma Strategy Partners GmbH, Reinach BL, Switzerland

for all publicly held registered shares with a nominal value of
CHF 0.40 each of

Acino Holding AG, Aesch BL, Switzerland

On October 4, 2013, Pharma Strategy Partners GmbH, Reinach BL («Pharma Strategy Partners»), published a public tender offer («Tender Offer» or «Offer») in accordance with article 22 et seq. of the Federal Stock Exchange and Securities Trading Act (*Bundesgesetz über die Börsen und den Effektenhandel*) for all publicly held registered shares of Acino Holding AG, Aesch BL («Acino»), with a nominal value of CHF 0.40 each (the «Acino Shares»). The offer price for each Acino Share amounts to CHF 115 net, less the gross amount of any dilution effects becoming effective prior to the settlement of the Tender Offer, as further described in the offer prospectus dated October 4, 2013 (the «Offer Prospectus»).

Definitive Final Result

Until the expiration of the additional acceptance period on December 5, 2013, 4:00 p.m. Central European Time (CET) 3,237,774 Acino Shares have been tendered under the Tender Offer. Pharma Strategy Partners and the persons acting in concert with it have not acquired any Acino Shares over the stock exchange or otherwise during the offer period and during the additional acceptance period. It results a participation in the aggregate of 3,237,774 Acino-Shares corresponding to 93.58% of the share capital and the voting rights of Acino.

The Acino shares held by Acino itself have been transferred to employees under the employee participation plan. 35 Acino Shares held by Acino itself, which have not been transferred to employees due to the termination of the employment of certain employees, have been tendered by Acino into the Offer.

The table below gives an overview of the definitive final result of the Offer:

| | Number of Acino Shares | Share Capital / Voting Rights | Success Rate |
|--|---------------------------|-------------------------------------|--------------|
| Acino Shares tendered under the Offer | 3,237,774 | 93.58 % | 93.58 % |
| Participation of Pharma Strategy Partners after the expiration of the additional acceptance period | 3,237,774 | 93.58 % | |

Considering the 21,562 Acino Shares which Pharma Strategy Partners has acquired via stock exchange since the expiration of the additional acceptance period, it results a participation in the aggregate of 3,259,336 Acino Shares, corresponding to 94.20% of the share capital and the voting rights of Acino as per December 9, 2013. Pharma Strategy Partners intends to effect a full takeover of Acino, and will de-list the Acino Shares from the stock exchange.

Satisfaction of the Conditions

Conditions (a), (b) and (c) according to Section B.6 (*Conditions*) of the Offer Prospectus are satisfied.

Conditions (d), (e), (f) and (g) remain in force until the settlement of the Offer.

Settlement

The Offer Price (CHF 115 per Acino-Share less the gross amount of any dilution effects) for the Acino Shares validly tendered during the Offer Period and the Additional Acceptance Period will be paid on December 12, 2013.

Sales Restrictions

The Tender Offer is subject to the sales restrictions according to the Offer Prospectus. The Offer Prospectus and all other tender offer documents are accessible under www.pharmastrategypartners.com.

Registered shares of Acino Holding AG

| | | |
|-----------------------|-----------------|---------------|
| Swiss Security Number | ISIN | Ticker Symbol |
| 2 119 090 | CH002 119 090 2 | ACIN |

Place and Date Reinach, December 11, 2013

Lead Financial Advisor:

Financial Advisor in the context of the public tender offer:

LAZARD

CREDIT SUISSE

